Stimwave Technologies, headquartered in Fort Lauderdale, Fla., received FDA clearance to market its Stimwave Freedom-8A SCS System.
Here are five notes:
1. The system is an eight-electrode wireless, micro-technology neuromodulation device intended for chronic back and leg pain.
2. The device is the first wireless, fully-programmable SCS neuromodulation device available on the market.
3. After receiving clearance, Stimwave, an innovator in wireless medical device technology, began commercializing the device and implanting the first patients earlier this quarter. The company plans to commercialize the device on a nationwide scale on the first of next year.
4. The device delivers small pulses of energy, in a fully-selectable manner, to eight electrodes placed near surrounding nerves, inciting a reaction that allows the brain to remap specific pain signals.
5. Medical professionals insert the device through a standard needle, without the need for general anesthesia or a large surgical incision.
More spine news:
8 things for spine surgeons to know for Thursday — Dec. 10, 2015
Stem cell, hormone combination therapy may enhance spinal fracture healing: 4 observations
White Plains Hospital welcomes neurosurgeon Dr. Adesh Tandon: 6 things to know